Page 24 - Acrobat J Trad-21-3-2566

J Thai Trad Alt Med Vol. 21 No. 3 Sep-Dec 2023 507

Editor’s Note

Editor’s Note

At present, the situation of COVID-19 second article, Randomized-Controlled Trial
pandemic has improved considerably, but to Compare the Efficacy of Andrographis

the global warming has been so worsening paniculata Powder and Favipiravir for the
that the United Nations Secretary-General Treatment of Mild COVID-19, is a high-quality
has deemed that it has become “Global and reliable study compared with other herbal

boiling’’. Moreover, the wars as well as internal clinical studies. But there are some limitations,
conflicts have been more violent especially including: (1) Thailand has got favipiravir

those between Russia and NATO members, indicated as a “standard therapy’’ despite its
Israel and the Gaza Strip (beginning on 7 lack of adequate “evidence’’. So, it is difficult
October 2023), and the Myanmar military and for this kind of research to use a placebo in

anti-government groups along the western the control group; and the difference is hard
border of Thailand. The Thai economy that to be measured. (2) COVID-19 is an emerging
has been recovering from the COVID-19 crisis disease. Although academics have gained

has to face rising challenges – the stock market much knowledge in a short period of time,
declining markedly and the new government’s many issues are still unknown. Importantly, the
economic stimulation measures not being so virus has been mutating all the time, resulting

hopeful. However, our journal is still making in difficulties in measuring the differences.
continuous development efforts. (3) The knowledge about the action mecha-

In this issue, the journal has twelve nism of A. paniculata (commonly known in
original articles. The first one, Efficacy of Thai as fa thalai chon) is very limited, result-
0.1% Chitosan-Curcuminoid Mouthwash ing in difficulties in making discussions and

in Treatment of Oral Lichen Planus and conclusions of the study results. Moreover,
Prevention of Disease Relapse, covers the there are other limitations regarding the study

results of its Phase 2 study in 20 participants products in terms of Good Agricultural Prac-
showing the clear efficacy of the product; so tice (GAP) and Good Manufacturing Practice
a Phase 2 study should be conducted. The (GMP) and Good Clinical Practice (GCP),